Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial.

Ribi, Karin; Luo, Weixiu; Colleoni, Marco; Karlsson, Per; Chirgwin, Jacquie; Aebi, Stefan; Jerusalem, Guy; Neven, Patrick; Di Lauro, Vincenzo; Gomez, Henry L; Ruhstaller, Thomas; Abdi, Ehtesham; Biganzoli, Laura; Müller, Bettina; Barbeaux, Annelore; Graas, Marie-Pascale; Rabaglio, Manuela; Francis, Prudence A; Foukakis, Theodoros; Pagani, Olivia; ... (2019). Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. British journal of cancer, 120(10), pp. 959-967. Springer Nature 10.1038/s41416-019-0435-4

Text s41416-019-0435-4.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (618kB)

BACKGROUND

In the phase III SOLE trial, the extended use of intermittent versus continuous letrozole for 5 years did not improve disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Intermittent therapy with 3-month breaks may be beneficial for patients' quality of life (QoL).

METHODS

In the SOLE QoL sub-study, 956 patients completed the Breast Cancer Prevention Trial (BCPT) symptom and further QoL scales up to 24 months after randomisation. Differences in change of QoL from baseline between the two administration schedules were tested at 12 and 24 months using repeated measures mixed-models. The primary outcome was change in hot flushes at 12 months.

RESULTS

There was no difference in hot flushes at 12 months between the two schedules, but patients receiving intermittent letrozole reported significantly more improvement at 24 months. They also indicated less worsening in vaginal problems, musculoskeletal pain, sleep disturbance, physical well-being and mood at 12 months. Overall, 25-30% of patients reported a clinically relevant worsening in key symptoms and global QoL.

CONCLUSION

Less symptom worsening was observed during the first year of extended treatment with the intermittent administration. For women experiencing an increased symptom burden of extended adjuvant endocrine therapy, an intermittent administration is a safe alternative.

CLINICAL TRIAL INFORMATION

Clinical trial information: NCT00651456.

Interest & Impact

Downloads

1 since deposited on 28 Nov 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item